Reports Q4 revenue $17.565M, consensus $17.68M. “The Theravance team delivered a strong performance in 2023, having achieved our financial objectives in the fourth quarter and exceeded our aggressive annual goal for YUPELRI hospital growth,” said Rick E Winningham, Chief Executive Officer. “We look forward to continuing YUPELRI net sales growth in 2024 and completing enrollment in the CYPRESS study in the second half of this year. Further, we are excited to host a virtual investor event in the second quarter, where both MSA thought leaders and members of Theravance’s senior management team will review the science underpinning our expectation that ampreloxetine can provide clinical benefits in MSA patients with nOH.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TBPH:
- TBPH Earnings this Week: How Will it Perform?
- Theravance Biopharma downgraded at Evercore ISI after Yupelri trial failure
- Theravance Biopharma downgraded to In Line from Outperform at Evercore ISI
- Theravance Biopharma reports PIFR-2 study missed primary endpoint
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue